Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 31, Supplement—April 2025
SUPPLEMENT ISSUE
Supplement

Respiratory Virus Detection and Sequencing from SARS-CoV-2–Negative Rapid Antigen Tests

Emmanuela Jules1, Charlie Decker1, Brianna Jeanne Bixler1, Alaa Ahmed, Zijing (Carol) Zhou, Itika Arora, Henok Tafesse, Hannah Dakanay, Andrei Bombin, Ethan Wang, Jessica Ingersoll, Kathy Bifulco, Jennifer K. Frediani, Richard Parsons, Julie Sullivan, Morgan Greenleaf, Jesse J. Waggoner, Greg S. Martin, Wilbur A. Lam, and Anne PiantadosiComments to Author 
Author affiliation: Emory University School of Medicine, Atlanta, Georgia, USA (E. Jules, C. Decker, B.J. Bixler, A. Ahmed, Z.(C.) Zhou, I. Arora, H. Tafesse, H. Dakanay, A. Bombin, E. Wang, J. Ingersoll, J. Sullivan, J.J. Waggoner, W.A. Lam, A. Piantadosi); Emory Integrated Genomics Core, Winship Cancer Institute of Emory University, Atlanta (A. Ahmed); Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta (K. Bifulco, J.K. Frediani, R. Parsons); The Atlanta Center for Microsystems Engineered Point-of-Care Technologies, Atlanta (J.K. Frediani, R. Parsons, J. Sullivan, M. Greenleaf); Georgia Clinical and Translational Science Alliance, Atlanta (M. Greenleaf); Emory University Division of Pulmonary, Allergy, Critical Care Medicine and Sleep Medicine, Atlanta (G.S. Martin); Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta (W.A. Lam); Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta, Atlanta (W.A. Lam)

Main Article

Table

Participant symptoms in study of respiratory virus detection and sequencing from SARS-CoV-2–negative rapid antigen tests*

Symptom Total participants, N = 53 Participants with a virus detected, n = 18† Participants with no virus detected, n = 35
Upper respiratory 47 (88.7) 17 (94.4) 30 (85.7)
Congestion/runny nose 37 (69.8) 15 (83.3) 22 (62.9)
Sore throat 33 (62.3) 14 (77.8) 19 (54.3)
Loss of sense of taste or smell
 7 (13.2)
 2 (11.1)
 5 (14.3)
Lower respiratory 43 (81.1) 15 (83.3) 28 (80.0)
Cough 39 (73.6) 15 (83.3) 24 (68.6)
Shortness of breath
 23 (43.4)
 6 (33.3)
 17 (48.6)
Gastrointestinal 15 (28.3) 6 (33.3) 9 (25.7)
Vomiting 4 (7.6) 3 (16.7) 1 (2.9)
Nausea 11 (20.8) 2 (11.1) 9 (25.7)
Diarrhea 2 (3.8) 1 (5.6) 1 (2.9)
Abdominal pain
 7 (13.2)
 2 (11.1)
 5 (14.3)
Systemic 35 (66.0) 13 (72.2) 22 (62.9)
Fever, temperature >100.4 18 (34.0) 7 (38.9) 11 (31.4)
Chills 24 (45.3) 11 (61.1) 13 (37.1)
Fatigue
 27 (50.9)
 11 (61.1)
 16 (45.71)
Other 41 (77.4) 16 (88.9) 25 (71.4)
Headache 30 (56.6) 13 (72.2) 17 (48.6)
Joint pain 14 (26.4) 3 (16.7) 11 (31.4)
Muscle pain 31 (58.5) 10 (55.6) 21 (60.0)

*Values are no. (%) participants reporting each symptom at the time of testing. For symptom categories, the number of participants with >1 symptom in that category is reported. †Includes 1 person in whom SARS-CoV-2 was detected at a low level and 17 persons in whom an alternative human pathogenic respiratory virus was detected.

Main Article

1These first authors contributed equally to this article.

Page created: March 31, 2025
Page updated: April 23, 2025
Page reviewed: April 23, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external